Wockhardt Limited
Investor Presentation By
- Dr. Murtaza Khorakiwala
Managing Director Q4FY15 & FY14-15
Wockhardt Limited Investor Presentation By Dr. Murtaza Khorakiwala - - PowerPoint PPT Presentation
Wockhardt Limited Investor Presentation By Dr. Murtaza Khorakiwala Managing Director Q4FY15 & FY14-15 Safe Harbor Statement Except for historical information contained herein, statements in this communication, which include words or
Investor Presentation By
Managing Director Q4FY15 & FY14-15
words or phrases such as “will”, “aim”, “will likely result”, “would”, “believe”, “may”, “expect”, “will continue”, “anticipate”, “estimate”, “intend”, “plan”, “contemplate”, “seek to”, “future”, “objective”, “goal”, “likely”, “project”, “should”, “potential”, “will pursue” and similar expressions or variations of such expressions may constitute “forward looking statements”. These forward looking statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially from those suggested by the forward looking statements. These risks and uncertainties include, but are not limited to our ability to successfully implement our strategy, our growth and expansion plans, obtain regulatory approvals, our provisioning policies, technological changes, investment and business income, cash flow projections, our exposure to market risks as well as other
reflect events or circumstances after the date thereof.
Investor Presentation May 2015 2
ROW operations Wockhardt Direct
USA UK, Ireland, France, Switz. India
Mexico
Investor Presentation May 2015 4
Direct Operations in India, USA and Europe
8600 Associates employed in 21 countries
UK Ireland
Investor Presentation May 2015 5
Manufacturing Locations globally
Ankleshwar Daman (2 Plants) Aurangabad (5 Plants) Baddi Chicago
Formulations APIs 9 sites in India
Investor Presentation May 2015 6
worldwide
Investor Presentation May 2015 8
EU GMP certification of Kadaiya facility.
in company's efforts towards compliance.
Discovery program in Anti-infective research in FY15. Also obtained QIDP status for its third NCE product WCK 4873 during this month. QIDP status allows for fast track review by US FDA and also grants a five year extensions to the drug patents in USA. Wockhardt is the only Indian company to receive QIDP status for its NCE products.
granted 82 patents during the Year taking the cumulative patents granted to 341.
Investor Presentation May 2015 10
Rs.crore Growth of 4% in Q4FY15 over Q4FY14
Investor Presentation May 2015 11
Rs.crore Growth of 11% in Q4FY15 over Q4FY14
Investor Presentation May 2015 12
Rs.crore De-growth of 55% in Q4FY15 over Q4FY14
Investor Presentation May 2015 14
Rs.crore Decline of 7% in FY 14-15 over FY 13-14
Investor Presentation May 2015 15
Rs.crore Declines by 16% in FY 14-15 over FY 13-14
Investor Presentation May 2015 16
Rs.crore Declines by 52% in FY 14-15 over FY 13-14
Investor Presentation May 2015 17
Investor Presentation May 2015 18
cumulative ANDA’s pending for approval is 69.
2,150 1,087
1,000 1,500 2,000 2,500 FY 13-14 FY 14-15
USA
Rs.cr.
$364 $179
UK Operations
Investor Presentation May 2015 19
Ireland Operations
Decline by 10% (11% in € terms) in FY 14-15.
964 1,405
100 300 500 700 900 1,100 1,300 1,500 FY 13-14 FY 14-15
UK
Rs.cr. £ 104 £ 141 176 158
100 150 200 250 FY 13-14 FY 14-15
Ireland
Rs.cr. € 22 € 20
Grows by 26% for Q4FY15. Grows by 19% for FY 14-15.
and Grows by 24% during FY 14-15.
products launched in FY 14-15 in India.
25% in Q4FY15 and grew by 3% during FY 14-15.
Investor Presentation May 2015 20
998 India 1235 India
302 Em 312 Em
200 400 600 800 1,000 1,200 1,400 1,600 1,800 FY 13-14 FY 14-15
India & Emerging Markets (Em)
Rs.cr.
Investor Presentation May 2015 21
For investor updates and communication please visit www.wockhardt.com For Information please contact Arun Khatanhar Tel.: +91 22 71596228 Akhatanhar@wockhardt.com